kanjinti | What is KANJINTI® | KANJINTI® (trastuzumab-anns)

Keyword	CPC	PCC	Volume	Score	Length of keyword
kanjinti	1.32	1	2392	54	8

Keyword	CPC	PCC	Volume	Score
kanjinti	1.55	0.1	6462	67
kanjinti chemo	0.33	0.7	9928	71
kanjinti package insert	1.37	0.4	3240	79
kanjinti j code	0.66	0.5	815	72
kanjinti vs herceptin	0.45	0.8	5265	89
kanjinti side effects	1.29	0.4	5369	57
kanjinti chpl	1.62	0.2	4722	5
kanjinti ema	1.14	0.4	458	41
kanjinti price	1.69	0.3	8275	55
kanjinti amgen	1.88	0.5	3682	93
kanjinti drug class	1.62	1	451	53
kanjinti copay card	0.03	0.3	1268	9
kanjinti chemotherapy	1.25	0.4	5413	59
kanjinti prescribing information	0.45	0.6	1154	36

Search Results related to kanjinti on Search Engine

What is KANJINTI® | KANJINTI® (trastuzumab-anns)
kanjinti.com

https://www.kanjinti.com/patient-resources/what-is-kanjinti

WEBKANJINTI ® is a prescription medicine used for the treatment of: Adjuvant Breast Cancer. KANJINTI ® is used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread ...

DA: 86 PA: 75 MOZ Rank: 41

Kanjinti Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/kanjinti.html

WEBMar 26, 2024 · Kanjinti is used to treat certain types of breast cancer or stomach cancer, sometimes in combination with other cancer medicines. Kanjinti is sometimes used when the cancer has spread to other parts of the body (metastatic). Kanjinti may also be used for purposes not listed in this medication guide.

DA: 23 PA: 10 MOZ Rank: 31

Dosing Schedule | KANJINTI® (trastuzumab-anns) for HCPs
kanjinti.com

https://www.kanjinti.com/hcp/dosing

WEBKANJINTI® is indicated: In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

DA: 53 PA: 11 MOZ Rank: 68

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab …
amgen.com

https://www.amgen.com/newsroom/press-releases/2019/06/fda-approves-amgen-and-allergans-kanjinti-trastuzumabanns-a-biosimilar-to-herceptin-trastuzumab

WEBKANJINTI is indicated: In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

DA: 11 PA: 7 MOZ Rank: 4

HIGHLIGHTS OF PRESCRIBING INFORMATION Adjuvant …
fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761073s000lbl.pdf

WEBKANJINTI is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer. (1.1, 1.2) the treatment of HER2 overexpressing metastatic gastric or...

DA: 94 PA: 1 MOZ Rank: 3

Kanjinti (Trastuzumab-anns for Injection): Side Effects, Uses ... - RxList
rxlist.com

https://www.rxlist.com/kanjinti-drug.htm

WEBOct 17, 2023 · Kanjinti (trastuzumab-anns) is a HER2 /neu receptor antagonist indicated for the treatment of HER2 overexpressing breast cancer and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. What Are Side Effects of Kanjinti? Kanjinti may cause serious side effects including: hives, …

DA: 70 PA: 36 MOZ Rank: 53

Kanjinti (trastuzumab - European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/documents/overview/kanjinti-epar-medicine-overview_en.pdf

WEBKanjinti is a cancer medicine used to treat the following conditions: • early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable.

DA: 65 PA: 60 MOZ Rank: 37

Kanjinti | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/kanjinti

WEBKanjinti is a cancer medicine used to treat the following conditions: early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable.

DA: 93 PA: 7 MOZ Rank: 18

Kanjinti - Chemocare
chemocare.com

https://chemocare.com/druginfo/kanjinti

WEBThis helps to slow or stop the spread of cancer cells. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. COMMON BRAND NAME(S): Herceptin, Herzuma, KANJINTI, Ogivri, Ontruzant, Trazimera.

DA: 2 PA: 50 MOZ Rank: 31

Patient Support Resources | KANJINTI®(trastuzumab-anns)
kanjinti.com

https://www.kanjinti.com/patient-resources/support

WEBKANJINTI ® is a prescription medicine used for the treatment of: Adjuvant Breast Cancer. KANJINTI ® is used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread ...

DA: 98 PA: 29 MOZ Rank: 84